TELA News and Press, TELA Bio Inc. From 03/27/20

TELA Bio, Inc.. (TELA) Q4 2019 Earnings Conference Call March 27, 2020 08:00 AM ET Company Participants Stuart Henderson - Vice President, Corporate Development and Investor Relations Antony Koblish - Co-founder, President, Chief Executive Officer Nora Brennan - Chief Financial O...

TELA Bio (NASDAQ: TELA ): Q4 GAAP EPS of -$1.22 misses by $0.65 . More news on: TELA Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

MALVERN, Pa., March 27, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today ...

MALVERN, Pa., March 11, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, announ...

MALVERN, Pa., Feb. 04, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstru...

MALVERN, Pa., Jan. 29, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstru...

TELA Bio (NASDAQ: TELA ) is up  5%  premarket on announcing preliminary Q4 and FY 2019 revenue. More news on: TELA Bio, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Preliminary fourth quarter 2019 revenue increased 94%-102% year-over-year to $4.7 million to $4.9 million Preliminary full year 2019 revenue increased 85%-87% year-over-year to $15.3 million to $15.5 million MALVERN, Pa., Jan. 10, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“...

TELA Bio (NASDAQ: TELA ): Q3 EPS of -$22.58 may not be comparable to consensus of -$0.57. More news on: TELA Bio, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Revenue increased 80% year-over-year to $4.0 million Completed initial public offering in November 2019, raising net proceeds of $50.7 million MALVERN, Pa., Dec. 18, 2019 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technolo...